Two subsidiaries of Nobel Biocare Holding AG, a world leader in the field of innovative implant-based dental restorations, filed a patent infringement lawsuit today in California against Neodent USA, Inc., alleging infringement of two patents relating to the innovative design of Nobel Biocare’s popular NobelActive® line of dental implants.
In March 2014, Neodent USA launched its line of “Drive CM” dental implants in the US. In its complaint, Nobel Biocare alleges that these implants, imported from Brazil, have striking similarities to the design of the NobelActive® implants which Nobel Biocare commercially launched in 2008. Further, Nobel Biocare asserts that Neodent USA has relied on Nobel Biocare’s history of successful clinical data in marketing the Neodent product.
The NobelActive® line has grown to become one of the world’s most popular dental implants, supported by Nobel Biocare’s commitment to Research & Development (R&D) spending, extensive clinical studies, and training programs for clinicians. Both US patents asserted in the lawsuit relate to technology for aiding the surgical installation and successful integration of the implants in a variety of patient bone types. Nobel Biocare asks the court for an injunction barring sales of Neodent’s infringing dental implants, payment of money damages due to Nobel Biocare’s lost sales, and to recover its attorney fees for the lawsuit.
Richard Laube, Nobel Biocare’s CEO, commented that: “We are committed to enforce our valuable intellectual property rights, which are the result of our industry-leading investment in R&D. We will not tolerate copies of our unique and patented dental implant designs.”
Nobel Biocare is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician® and DTX Studio™) and biomaterials (creos™). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland. Production takes place at six sites located in the United States, Sweden, Japan and Israel. Products and services are available in over 80 countries through subsidiaries and distributors.